

1 **TITLE PAGE**

2 **Complete title:** Eustachian Tube Symptoms are Frequent in Chronic Rhinosinusitis and  
3 Respond Well to Endoscopic Sinus Surgery

4 **Authors:** Anastasios Maniakas, MD<sup>1,2</sup>, Martin Desrosiers, MD, FRCSC<sup>1,2</sup>, Marc-Henri Asmar,  
5 MD<sup>1</sup>, Mohammad Al Falasi, MD<sup>4</sup>, Leandra Mfuna Endam, MSc<sup>1</sup>, Claire Hopkins, MD, FRCS<sup>5</sup>,  
6 Carl Philpott, MB ChB, MD, FRCS(ORL-HNS)<sup>6</sup>, Sally Erskine MB BS, DOHNS, MRCS<sup>6</sup>,  
7 Rupert Smith MRes<sup>6</sup>, Shaun Kilty, MD, FRCSC<sup>3</sup>

8 <sup>1</sup>Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM),  
9 Montreal, QC, Canada; <sup>2</sup>Division of Otolaryngology-Head & Neck Surgery, Centre  
10 Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada; <sup>3</sup>Department of  
11 Otolaryngology-Head and Neck Surgery, The University of Ottawa, Ottawa, ON, Canada;  
12 <sup>4</sup>Department of Otolaryngology-Head and Neck Surgery, Tawam Hospital, United Arab  
13 Emirates; <sup>5</sup>Department of Ear, Nose & Throat, Guy's and St Thomas' Hospital, London,  
14 UK; <sup>6</sup>Norwich Medical School, University of East Anglia, Norwich, UK.

15  
16 **Statements:** This material has never been published and is not currently under evaluation in any  
17 other peer-reviewed publication. The authors have received funding through the Canadian  
18 Institutes of Health Research (CIHR) & the Fonds de Recherche du Québec-Santé (FRQS).

19  
20 **Presentation:** This manuscript was presented at the American Academy of Otolaryngology-Head  
21 & Neck Surgery Annual Meeting in San Diego, CA, on September 20<sup>th</sup>, 2016.

22  
23 **Corresponding author:**

24 Shaun Kilty, MD, FRCSC  
25 Department of Otolaryngology-Head and Neck Surgery  
26 The Ottawa Hospital, University of Ottawa  
27 S3 501 Smyth Rd  
28 Ottawa, Ontario K1H 8L6  
29 Tel: (613) 562-5700  
30 Fax: (613) 562-5323  
31 Email: kiltysj@gmail.com  
32

33 **Short title:** Eustachian tube dysfunction in CRS

34 **Keywords:** Chronic Rhinosinusitis, Eustachian tube, Endoscopic Sinus Surgery, SNOT-22,  
35 Case-control study, Prospective trial

36 No conflict of interest

37 **ABSTRACT (250 max)**

38 **Objective:** Symptoms of Eustachian tube (ET) dysfunction are seldom assessed in patients with  
39 chronic rhinosinusitis (CRS). The SNOT-22 quality-of-life tool includes two questions that  
40 specifically screen for symptoms of ET dysfunction ('Ear Fullness'; 'Ear Pain'). The purpose of  
41 this study was to determine the extent to which these ET symptoms were present in patients with  
42 CRS, and whether these symptoms respond to endoscopic sinus surgery (ESS).

43 **Study design:** Prospective cohort studies

44 **Setting:** Secondary and tertiary care centres

45 **Subjects & Methods:** SNOT-22 data collected at time of recruitment into IRB-approved clinical  
46 trials or case-control studies in CRS was pooled to provide a cross section of the frequency and  
47 severity of ET dysfunction in CRS patients. When applicable to the trials, the SNOT-22 was  
48 repeated at least 3 months following ESS.

49 **Results:** Five trials rendering 131 patients were available for assessment. The control group  
50 comprised of 251 participants. 'Ear Fullness' of  $\geq 1$  was reported in 80/131 CRS patients  
51 compared to 45/251 control patients, (Mean=3.08 vs. 1.84;  $p < 0.001$ ). 'Ear Pain' of  $\geq 1$  was  
52 reported in 39/131 CRS patients compared to 33/251 control patients (Mean=2.31 vs.1.82;  
53  $p = 0.042$ ). Following ESS, mean 'Ear Fullness' and 'Ear Pain' scores decreased to 1.17 and 0.73,  
54 respectively ( $p < 0.001$ ).

55 **Conclusion:** Symptoms suggestive of ET dysfunction are frequent in CRS, and for most patients  
56 the symptoms will decrease following intervention, to a level comparable with a non-CRS  
57 population. Patients' whose ET symptoms do not respond to ESS may represent a target  
58 population for emerging therapeutic options for ET dysfunction.

59

60 **INTRODUCTION (manuscript max is 3000 words – Intro to Conclusion)**

61         The Eustachian tube (ET) provides the physiological functions of middle ear pressure  
62 equalization, protection, and clearance. ET dysfunction can be divided into two categories:  
63 functional – defined as the inability to actively dilate the tube; or mechanical – defined as  
64 secondary to inflamed mucosa, middle ear disease, hypertrophic adenoids, nasopharyngeal  
65 neoplasm, and/or polyps. Tubal integrity and susceptibility to dysfunction are also known to be  
66 influenced by allergy and sinonasal disease, especially when these disorders are chronic. Chronic  
67 rhinosinusitis (CRS) is one of the most common inflammatory diseases of the nose and paranasal  
68 sinuses affecting up to 10% of the population<sup>1,2</sup>. The Sino-Nasal Outcome Test (SNOT-22) is a  
69 self-reported symptom-based rhinosinusitis outcome measure tool that is widely accepted and  
70 validated for patients with CRS<sup>3</sup>. Patients complete the questionnaire by grading their symptom  
71 severity from 0 (not a problem) to 5 (problem as bad as it can be). The SNOT-22 includes two  
72 questions related to ET dysfunction, that of “ear fullness” and “ear pain”. These symptoms can  
73 be quite debilitating to patients<sup>4</sup>, leading to increased absenteeism from work or hindered social  
74 interactions, and thus deserve further investigation. There have been reports that rhinosinusitis  
75 and ET dysfunction can be associated and that endoscopic sinus surgery (ESS) can alleviate such  
76 symptoms<sup>5</sup>, although it remains to be thoroughly studied.

77         The aims of this study were to determine the prevalence and severity of symptoms  
78 associated with ET dysfunction in CRS patients compared to a control group without known  
79 otologic disease or CRS, and to evaluate the evolution of these symptoms in CRS patients  
80 following ESS.

81

82

83 **METHODS**

84 *Chronic rhinosinusitis patients*

85 SNOT-22 data from five institutional review-board-approved prospective clinical trials or  
86 case-control studies including both CRS patients with and without nasal polyposis were collected  
87 and evaluated. Patients had to have had at least a SNOT-22 completed on the day of surgery to  
88 be eligible for this study, while post-ESS SNOT-22 scores were collected from the same patients,  
89 when available, at least 3 months following ESS. All patients included in these clinical trials  
90 were considered patients at ‘high-risk’ of CRS recurrence according to our group’s previously  
91 described criteria<sup>6</sup>.

92 *Control group*

93 Control group SNOT-22 data were retrieved from the Chronic Rhinosinusitis  
94 Epidemiology Study (CRES)<sup>7,8</sup> and the ongoing Socioeconomic Cost of Chronic Rhinosinusitis  
95 Study (SocCoR)<sup>9</sup> database originating in the United Kingdom. Family and friends of patients  
96 attending otolaryngology outpatient clinics and hospital and university staff were recruited as  
97 controls. This non-CRS population had no self-reported otologic or nasal disease, active  
98 treatment for chronic conditions, nor any hospital admissions in the preceding 12 months.

99 *Statistical analyses*

100 All data were tabulated using Microsoft Excel and all statistical analyses were performed  
101 using STATA 13.1 (STATA Corp LP, College Station, TX). Absolute and relative frequencies  
102 are presented for categorical and ordinal variables. A two-tailed Pearson Chi-square or Fisher’s  
103 exact test was used to compare the prevalence and proportion of ET dysfunction symptoms  
104 between CRS and control groups. Comparison of symptom severity and overall SNOT-22 scores  
105 between groups and before and after ESS were evaluated using a two-sample Student T-test with  
106 unequal variances. For all statistical analyses, a  $p < 0.05$  was considered statistically significant.

107 **RESULTS**

108 *Demographics*

109 A total of 131 patients at ‘high-risk’ of CRS recurrence were included in the CRS group  
110 and completed a SNOT-22 on the day of surgery. The control group comprised of 251  
111 participants having completed the SNOT-22 questionnaire on a single occasion.

112 **Table 1: Demographics and SNOT-22 findings**

113

	<b>CRS group (N=131)</b>	<b>Control group (N=251)</b>	<b>P value</b>
<b>Age (range)</b>	52.7 (21-86)	47.5 (19-80)	
<b>Female</b>	52	143	<0.001
<b>Male</b>	79	96	
<b>SNOT-22 (SD)</b>	46.4 (20.6)	12 (13.6)	<0.001
<b>No. patients with Ear fullness <math>\geq</math>1 (%)</b>	80 (61.1%)	45 (17.9%)	<0.001
<b>No. patients with Ear pain <math>\geq</math>1 (%)</b>	39 (29.8%)	33 (13.2%)	<0.001
<b>Mean Ear fullness symptom score if Ear fullness <math>\geq</math>1 (SD)</b>	3.08 (1.25)	1.84 (0.79)	<0.001
<b>Mean Ear pain symptom score if Ear pain <math>\geq</math>1 (SD)</b>	2.31 (0.95)	1.82 (0.5)	0.042

114

115

116 *SNOT-22 according to ear symptom in CRS patients*

117 The mean SNOT-22 score for CRS patients with a score of  $\geq$ 1 for ‘ear fullness’ was  
118 significantly higher than in CRS patients with a score of 0 (53.2 vs. 35.8;  $p<0.001$ ). Similarly,  
119 CRS patients with a score of  $\geq$ 1 for ‘ear pain’ had a significantly higher overall SNOT-22 score  
120 than CRS patients with a score of 0 (63.4 vs. 39.2;  $p<0.001$ ).

121 *Evolution of ‘ear fullness’*

122 Of the 80 CRS patients with a score of  $\geq$ 1 for ‘ear fullness’, 66 (82.5%) completed a  
123 SNOT-22 score between 3 and 4 months post-ESS. Mean ear fullness score statistically  
124 significantly decreased post-ESS to 1.17 (Figure 1), while 78.8% (52 of 66) reported an  
125 improvement in their ‘ear fullness’ score (mean improvement =2.5; range 1 to 5). Five patients  
126 (7.6%) reported symptom deterioration.

127 *Evolution of ‘ear pain’*

128           Of the 39 CRS patients with a score of  $\geq 1$  for ‘ear pain’, 30 (76.9%) completed a SNOT-  
129 22 score between 3 and 4 months post-ESS. Mean ear pain score statistically significantly  
130 decreased post-ESS to 0.73 (Figure 2), while 73.3% (22 of 30) reported an improvement in their  
131 ‘ear fullness’ score (mean improvement =2.2; range 1 to 3). Three patients (10%) reported  
132 symptom deterioration.

133

134 **DISCUSSION**

135           The current literature on ET dysfunction symptoms in patients with CRS is very limited.  
136 To our knowledge, this is the first study where ET dysfunction symptoms are prospectively  
137 evaluated and compared to a control group. Our findings reveal that symptoms suggestive of ET  
138 dysfunction are quite frequent in patients with CRS who fail maximal medical therapy and  
139 require ESS. More specifically, ‘ear fullness’ was a reported symptom in close to two thirds of  
140 patients, while ‘ear pain’ was reported in one third of CRS patients. These rates are significantly  
141 higher than Stoikes et al.<sup>5</sup>’s previously published findings (42% and 15% respectively).  
142 Furthermore, compared to the control group, when present both ‘ear fullness’ and ‘ear pain’ were  
143 significantly more prevalent and debilitating in CRS patients. Overall, it is clear that the  
144 prevalence of ET dysfunction in CRS has been greatly underappreciated, particularly in patients  
145 with severe disease.

146           Our second significant finding is the important treatment effect CRS patients had  
147 following ESS. Approximately 75% of reported ‘ear fullness’ and ‘ear pain’ had a favourable  
148 evolution post-ESS, with a mean improvement of more than 2 points on 5. These findings are  
149 slightly inferior to Stoikes et al.<sup>5</sup>’s findings (84.3% and 84%, respectively), although one must

150 consider the important recall bias and variability of post-ESS response timeframe of their  
151 retrospective study. Others have demonstrated the improvement of ear-associated SNOT-22  
152 symptoms without however providing a detailed categorisation<sup>10,11</sup>.

### 153 ***Limitations***

154         The proportion of females were significantly higher in the control group, and as it has  
155 been described in the literature, females tend to report higher SNOT-22 scores<sup>7</sup>. This  
156 unfortunately can hinder our group comparability. However, when males and females average  
157 SNOT-22 scores were compared within each group, both CRS and control group females had  
158 proportionally higher scores. Overall, the effect of this inter-group difference can only lead to an  
159 underestimation of the symptoms in the CRS group, which in turn strengthens the already  
160 significant findings we have reported. Furthermore, it is important to note that our follow-up  
161 period was short and we therefore are unable assess the long-term effect of ESS on ET  
162 dysfunction-associated symptoms.

### 163 ***Future directions***

164         Although this prospective study on ET dysfunction-associated symptoms demonstrates  
165 the effect CRS can have on such symptoms, a more thorough evaluation of ET dysfunction with  
166 the Eustachian Tube Dysfunction Questionnaire (ETDQ-7)<sup>12</sup> would be most appropriate.  
167 Furthermore, what remains to be addressed is the management of CRS patients with persistent  
168 and debilitating ET dysfunction symptoms, even following ESS where there remains a  
169 prevalence of 7.6% for ear fullness and 10% for ear pain). Alternative management is available  
170 and should be considered; one of these may be the novel surgical technique of ET balloon  
171 dilatation that has been shown to be a possible therapeutic option<sup>13</sup> but remains to be validated  
172 with RCTs and long-term follow-up studies.

173

174 **CONCLUSION**

175           Symptoms suggesting ET dysfunction have been underestimated in the CRS population,  
176 especially in patients with severe disease. Our findings depict the substantial prevalence of ‘ear  
177 fullness’ and ‘ear pain’ in patients undergoing ESS for CRS, compared to a control population,  
178 while also demonstrating the strong positive treatment effect of ESS on these symptoms. We  
179 suggest that further study into ET dysfunction in CRS is needed to better understand the origin of  
180 these symptoms and to evaluate ideal treatment options for patients whose symptoms do not  
181 respond to surgical treatment of CRS.

182

183

184

185

186

187

188

189

190

191

192

193

194 **REFERENCES**

- 195 1.       Hastan D, Fokkens WJ, Bachert Cet al. Chronic rhinosinusitis in Europe--an underestimated  
196 disease. A GA(2)LEN study. Allergy 2011; 66:1216-1223.



- 197 2. Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. The  
198 Laryngoscope 2003; 113:1199-1205.
- 199 3. Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal  
200 Outcome Test. Clin Otolaryngol 2009; 34:447-454.
- 201 4. Bakhshae M, Ardakani HP, Ghazizadeh AH, Movahed R, Jarahi L, Rajati M. Middle ear function  
202 in sinonasal polyposis. European archives of oto-rhino-laryngology : official journal of the  
203 European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German  
204 Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2016; 273:2911-2916.
- 205 5. Stoikes NF, Dutton JM. The effect of endoscopic sinus surgery on symptoms of eustachian tube  
206 dysfunction. Am J Rhinol 2005; 19:199-202.
- 207 6. Maniakas A, Desrosiers M. Azithromycin add-on therapy in high-risk postendoscopic sinus  
208 surgery patients failing corticosteroid irrigations: A clinical practice audit. American journal of  
209 rhinology & allergy 2014; 28:151-155.
- 210 7. Erskine SE, Hopkins C, Clark A et al. SNOT-22 in a control population. Clin Otolaryngol 2016.
- 211 8. Philpott C, Erskine S, Hopkins C et al. A case-control study of medical, psychological and socio-  
212 economic factors influencing the severity of chronic rhinosinusitis. Rhinology 2016; 54:134-140.
- 213 9. Smith R, Erskine S, Philpott C. Preliminary results of a questionnaire based study to identify the  
214 socio-economic costs of Chronic Rhinosinusitis (CRS) to patients and society. Available at:  
215 <http://www.britishrhinologicalsociety.org.uk/meetings/abstractdisplay.php?ID=161>.
- 216 10. Kennedy JL, Hubbard MA, Huyett P, Patrie JT, Borish L, Payne SC. Sino-nasal outcome test  
217 (SNOT-22): a predictor of postsurgical improvement in patients with chronic sinusitis. Ann  
218 Allergy Asthma Immunol 2013; 111:246-251.e242.
- 219 11. Yu VM, Yu JM. Improvement in Eustachian Tube Function after Endoscopic Sinus Surgery for  
220 Polypoid Chronic Rhinosinusitis (Abstract). Otolaryngology - Head & Neck Surgery 2013.
- 221 12. McCoul ED, Anand VK, Christos PJ. Validating the clinical assessment of eustachian tube  
222 dysfunction: The Eustachian Tube Dysfunction Questionnaire (ETDQ-7). The Laryngoscope 2012;  
223 122:1137-1141.
- 224 13. Williams B, Taylor BA, Clifton N, Bance M. Balloon dilation of the Eustachian tube: a  
225 tympanometric outcomes analysis. J Otolaryngol Head Neck Surg 2016; 45:13.

226

227

228

229


230

231

232

233


234 **Figure 1: Evolution of mean ear fullness score following endoscopic sinus surgery**



235

236

237 **Figure 2: Evolution of mean ear pain score following endoscopic sinus surgery**



238